Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.33
+0.07 (1.33%)
Dec 5, 2025, 4:00 PM EST - Market closed
Candel Therapeutics Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Candel Therapeutics stock ranges from a low of $7.00 to a high of $25. The average analyst price target of $19.43 forecasts a 264.54% increase in the stock price over the next year.
Price Target: $19.43 (+264.54%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Candel Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +350.28% | Nov 14, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $15 | Buy | Initiates | $15 | +181.43% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +331.52% | Sep 29, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Hold Downgrades $13 → $7 | Strong Buy → Hold | Downgrades | $13 → $7 | +31.33% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +331.52% | Jun 30, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.42
from -1.74
EPS Next Year
-1.01
from -0.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.43 | -0.53 | |
| Avg | -0.42 | -1.01 | |
| Low | -0.42 | -1.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.